Core Insights - The article discusses the evolution of AI commercialization, focusing on the experiences and insights of Yin Qi, founder of Megvii Technology, and his current role at StepFun. It highlights the challenges faced in the AI 1.0 era and the shift towards more viable business models in the AI 2.0 landscape. Group 1: AI Commercialization Challenges - Yin Qi reflects on the difficulties of closing the commercial loop during the AI 1.0 era, which significantly impacted his ventures [3] - He emphasizes that once a business model fails, it is challenging to revert, leading to a lack of scalable profits and viable products [4] - The majority of the "Six Little Tigers" in the AI sector are still in the early stages of commercialization, struggling to find effective business models [4] Group 2: Insights on Competitors and Market Dynamics - Yin Qi expresses skepticism about the commercialization strategies of many AI startups in Silicon Valley, noting that Google has an advantage due to its established revenue streams [4] - He identifies xAI, associated with Tesla, as having a potentially successful commercial model due to its strong integration of software and hardware capabilities [5] Group 3: StepFun's Strategic Direction - StepFun has recently secured over 5 billion RMB in funding, setting a record for single financing rounds in the domestic large model sector [6] - The company aims to combine AI with smart terminals, focusing on hardware development alongside foundational model research [7][10] - StepFun's recent release of the Step3-VL-10B model demonstrates superior performance in benchmarks compared to larger models, indicating a strong position in the market [8] Group 4: Talent and Team Composition - StepFun's team comprises top talents from Megvii and Microsoft, maintaining a high density of expertise and a balanced skill set [12] - Yin Qi hopes to attract back some of the talent that has left for other companies in the sector, emphasizing the importance of a strong team for future success [13] Group 5: Long-term Vision and Philosophy - Yin Qi advocates for a long-term approach to business, focusing on delivering tangible commercial results rather than merely pursuing theoretical advancements [15] - He acknowledges a shift from a passionate to a more pragmatic mindset, prioritizing clear customer and commercial value in AI developments [15]

Group 1 - The company, 康臣药业 (01681), announced a share buyback plan from October 14, 2025, to December 17, 2025 [1] - A total of 8.385 million shares will be repurchased and subsequently canceled on January 16, 2026 [1]

Core Viewpoint - Kangchen Pharmaceutical (01681) announced a share buyback plan from October 14, 2025, to December 17, 2025, with the intention to cancel 8.385 million shares on January 16, 2026 [1] Summary by Category - **Company Actions** - The company plans to repurchase shares during the specified period [1] - A total of 8.385 million shares will be canceled following the buyback [1] - **Financial Implications** - The share buyback and subsequent cancellation may impact the company's share structure and potentially enhance shareholder value [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 重新提交 公司名稱： 康臣葯業集團有限公司 呈交日期： 2026年1月19日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | | 是 | | | | | 證券代號 (如上市) | 01681 | 說明 | | | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 事件 | | | 已發行股份（不包括庫存股份）變動 | | 庫 ...

Core Viewpoint - Kangchen Pharmaceutical (01681) announced the cancellation of 8.385 million repurchased shares on January 16, 2026, alongside the issuance of 191,000 shares through the exercise of stock options under a plan adopted on December 2, 2013 [1] Group 1 - The company will cancel a total of 8.385 million shares that were previously repurchased [1] - On the same date, the company will issue 191,000 shares as a result of exercising stock options [1] - The stock option plan was originally adopted on December 2, 2013 [1]

智通财经APP讯，康臣药业(01681)发布公告，该公司于2026年1月16日注销838.5万股已回购股份。 于同日，根据于2013年12月2日采纳的购股权计划行使购股权而发行19.1万股。 ...

格隆汇1月18日丨康臣药业(01681.HK)发布公告，2026年1月16日注销838.5万股购回股份。 ...

翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 康臣葯業集團有限公司 呈交日期： 2026年1月18日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 FF305 | 第一章節 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | | 是 | | | | 證券代號 (如上市) | 01681 | 說明 | | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | | ...

Group 1 - The company, 康臣药业 (01681), announced a share buyback plan, intending to repurchase 100,000 shares at a cost of HKD 1.5505 million [1]

Group 1 - The company, 康臣药业 (01681), announced a share buyback of 100,000 shares at a cost of HKD 1.5505 million on January 6, 2026 [1]